Project Grant R01HL181429
Award Date 9/1/26
Completion Date 5/31/31
Dollars Obligated $768K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
- The National Heart Lung and Blood Institute (NHLBI), a component of the Department of Health and Human Services National Institutes of Health, awarded $743,131 to the University of Wisconsin - Madison on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate regulatory mechanisms of the vessel wall in deep vein thrombosis. The research addresses thrombospondin-1 (TSP1), a matricellular protein upregulated in endothelial cells during DVT. The project tests...
- The National Heart, Lung, and Blood Institute awarded the University of Washington $1.608 million on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate genomic and proteomic determinants of recurrent venous thromboembolism. The research addresses the high rate of recurrent venous thromboembolism (VTE) events—either deep vein thrombosis or pulmonary embolism—occurring in 20–30% of survivors within five years. Current anticoagulant therapies, while...
- The National Heart Lung and Blood Institute awarded The Johns Hopkins University $175,874 on July 6, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a prospective, three-center cohort study investigating clinical risk factors and biomarkers for recurrent venous thromboembolism in children with cardiac disease. The research addresses the elevated risk of recurrent VTE events—including deep vein thrombosis and pulmonary embolism—in children with congenital and...
- The National Heart, Lung, and Blood Institute awarded The Washington University $803,772 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of the mitochondrial calcium uniporter in platelet function and thrombosis. The research addresses ischemic stroke prevention through basic and translational science. Approximately 700,000 people in the United States experience ischemic stroke annually, and current acute treatments restrict...
- The National Heart, Lung, and Blood Institute awarded the University of Illinois $1.6 million under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to investigate GA12-dependent mechanisms of basal and regulated endothelial cell von Willebrand factor (VWF) secretion. This is a Project Grant (R01HL186410). The research addresses microvascular thrombotic occlusions in inflammatory conditions such as sepsis and sickle cell disease, where elevated VWF plasma levels...
- The National Heart, Lung, and Blood Institute awarded The Washington University $764,681 under the Cardiovascular Diseases Research program (CFDA 93.837) on May 1, 2026, to conduct research into a multipotent fibroblast population and platelet-derived growth factor receptor beta–dependent immuno-fibrotic responses in heart failure. The research addresses cardiac fibrosis and left ventricular dysfunction in heart failure by investigating a novel population of stem cell antigen-1–expressing,...
- The National Heart, Lung, and Blood Institute awarded New York University $836,736 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate endothelial mechanosensing of circulatory flow in health and disease. The project will examine how endothelial cells lining blood and lymphatic vessels respond to fluid flow forces, with focus on the roles of PLXND1 (a transmembrane semaphorin receptor) and KLF2 (a transcription factor) in endothelial responses to...
- The National Heart, Lung, and Blood Institute awarded Lawrence Technological University $444,589 on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop multiscale computational modeling for assessing shear-induced bleeding risk in blood-contacting medical devices. The research addresses device-induced complications in blood-contacting medical devices used to manage and treat heart conditions. The project develops physics-based computational models to...
- The National Heart, Lung, and Blood Institute awarded Worcester Polytechnic Institute $532,935 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of the endothelial glycocalyx in sepsis-induced coagulopathy. The research targets sepsis-associated coagulopathy, a condition characterized by uncontrolled thrombosis, large vessel occlusion, and stroke that resists traditional anticoagulation therapies. The project will examine how sepsis...
- The National Heart, Lung, and Blood Institute awarded Emory University $221,270 on September 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of microvascular rheology and transfusion in thrombosis during sepsis. The award is a project grant with period of performance through August 31, 2027. The project uses state-of-the-art microfluidics assays to characterize how red blood cell aggregation and membrane deformability affect endothelial cell...